Mercado de síndrome de dificultad respiratoria aguda (SDRA) de Asia y el Pacífico, por causa (enfermedad por coronavirus 2019 (COVID-19), sepsis, inhalación de sustancias nocivas, neumonía grave y otras), tipo (diagnóstico y tratamiento), vía de administración (oral, parenteral y otras), usuario final (hospitales, clínicas especializadas, atención médica domiciliaria y otros), canal de distribución (licitación directa, farmacia hospitalaria, farmacia minorista, farmacia en línea y otros), país (Japón, China, Corea del Sur, India, Australia, Singapur, Tailandia, Malasia, Indonesia, Filipinas, Vietnam y resto de Asia y el Pacífico), tendencias de la industria y pronóstico hasta 2029.
Análisis y perspectivas del mercado : mercado del síndrome de dificultad respiratoria aguda (SDRA) en Asia y el Pacífico
Se espera que el mercado del síndrome de dificultad respiratoria aguda (SDRA) de Asia y el Pacífico gane crecimiento de mercado en el período de pronóstico de 2022 a 2029. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 11,1% en el período de pronóstico de 2022 a 2029 y se espera que alcance los USD 4.165,51 millones para 2029. La creciente prevalencia de COVID-19 actúa como impulsor del crecimiento del mercado del síndrome de dificultad respiratoria aguda (SDRA).
El síndrome de dificultad respiratoria aguda (SDRA) es una lesión pulmonar potencialmente mortal que permite que el líquido se filtre a los pulmones. La mayoría de las personas que padecen SDRA ya están en el hospital por un traumatismo o enfermedad como la COVID-19. El síndrome suele producirse cuando se acumulan líquidos en los diminutos sacos de aire elásticos llamados alvéolos de los pulmones. Esta acumulación de líquido hace que llegue menos oxígeno al torrente sanguíneo. Esto priva a los órganos de obtener suficiente oxígeno para su funcionamiento normal. Las personas con otras enfermedades desarrollan SDRA en cuestión de horas o días después de la lesión o infección desencadenante. El riesgo de muerte aumenta con la edad y, según la gravedad de la enfermedad, a los pacientes les resulta difícil sobrevivir al síndrome. Una enfermedad o lesión grave que provoque daño a los sacos de membrana de los pulmones provoca SDRA. Las causas subyacentes más comunes de dichas enfermedades incluyen sepsis , inhalación de sustancias nocivas, neumonía grave, lesiones en la cabeza, el pecho u otras lesiones importantes, enfermedad por coronavirus 2019 (COVID-19) y otras.
La creciente prevalencia e incidencia de lesiones pulmonares agudas, la amplia gama de factores de riesgo de SDRA y la aceleración del número de pacientes con COVID-19 con SDRA actúan como impulsores del mercado del síndrome de dificultad respiratoria aguda (SDRA). Otros factores que se prevé que impulsen el crecimiento del mercado del síndrome de dificultad respiratoria aguda (SDRA) en Asia y el Pacífico incluyen la creciente tasa de contaminación del aire y enfermedades relacionadas con el estilo de vida y el aumento de las tasas de accidentes y traumatismos que provocan SDRA.
Sin embargo, factores como las complicaciones asociadas con los tratamientos, el alto costo de los dispositivos y tratamientos están obstaculizando el crecimiento del mercado del síndrome de dificultad respiratoria aguda (SDRA) de Asia-Pacífico. Por otro lado, la creciente población geriátrica, el aumento del gasto en atención médica y las iniciativas estratégicas de los actores del mercado actúan como una oportunidad para el crecimiento del mercado del síndrome de dificultad respiratoria aguda (SDRA) de Asia-Pacífico. Las estrictas regulaciones para la aprobación y los múltiples desafíos que enfrentan las enfermeras de la UCI son el desafío clave del mercado al que se enfrenta el mercado del síndrome de dificultad respiratoria aguda (SDRA) de Asia-Pacífico.
El informe de mercado del síndrome de dificultad respiratoria aguda (SDRA) proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado del síndrome de dificultad respiratoria aguda (SDRA), comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado del síndrome de dificultad respiratoria aguda (SDRA)
El mercado del síndrome de dificultad respiratoria aguda (SDRA) está segmentado en función de la causa, el tipo, la vía de administración, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
- En función de la causa, el mercado del síndrome de dificultad respiratoria aguda (SDRA) de Asia y el Pacífico se segmenta en enfermedad por coronavirus 2019 (COVID-19), sepsis, inhalación de sustancias nocivas, neumonía grave y otras. En 2022, se espera que el segmento de la enfermedad por coronavirus 2019 (COVID-19) domine el mercado, ya que el número de casos en la región fue alto desde su origen en China.
- Según el tipo, el mercado del síndrome de dificultad respiratoria aguda (SDRA) de Asia y el Pacífico se segmenta en diagnóstico y tratamiento. En 2022, se espera que el segmento de diagnóstico domine el mercado debido al creciente número de hospitales e instalaciones de diagnóstico para brindar tratamientos oportunos.
- Según la vía de administración, el mercado del síndrome de dificultad respiratoria aguda (SDRA) de Asia y el Pacífico se segmenta en oral, parenteral y otros. El segmento parenteral se segmenta a su vez en intramuscular e intravenoso. En 2022, se espera que el segmento parenteral domine el mercado debido a la gran cantidad de actores del mercado que operan en el segmento.
- En función del usuario final, el mercado del síndrome de dificultad respiratoria aguda (SDRA) de Asia y el Pacífico se segmenta en hospitales, clínicas especializadas, atención médica domiciliaria y otros. En 2022, se espera que el segmento de hospitales domine el mercado, ya que la mayoría de las personas prefieren los hospitales para el diagnóstico seguido de los tratamientos.
- Sobre la base del canal de distribución, el mercado del síndrome de dificultad respiratoria aguda (SDRA) de Asia y el Pacífico se segmenta en licitación directa, farmacia hospitalaria, farmacia minorista, farmacia en línea y otros. En 2022, se espera que el segmento de licitación directa domine el mercado debido al precio justo de los productos vendidos por los fabricantes.
Análisis del mercado del síndrome de dificultad respiratoria aguda (SDRA) a nivel de país
Se analiza el mercado del síndrome de dificultad respiratoria aguda (SDRA) y se proporciona información sobre el tamaño del mercado por país, cinco segmentos notables como causa, tipo, vía de administración, usuario final y canal de distribución como se mencionó anteriormente.
Los países cubiertos en el informe de mercado del síndrome de dificultad respiratoria aguda (SDRA) son Japón, China, Corea del Sur, India, Australia, Singapur, Tailandia, Malasia, Indonesia, Filipinas, Vietnam y el resto de Asia-Pacífico.
Se espera que el segmento parenteral en Japón crezca a la tasa más alta en el período de pronóstico de 2022 a 2029 debido al creciente avance tecnológico en el país. El segmento parenteral en China es el segundo que domina el mercado debido al aumento de casos de enfermedades respiratorias crónicas y la alta adopción de diagnósticos adecuados. Corea del Sur es el tercer líder en el crecimiento del mercado de Asia-Pacífico y el segmento parenteral domina en este país debido al creciente número de centros de biotecnología y actividades de investigación.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Asia-Pacífico y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.
Las crecientes actividades estratégicas de los principales actores del mercado para mejorar la conciencia sobre el tratamiento del síndrome de dificultad respiratoria aguda (SDRA) están impulsando el crecimiento del mercado del síndrome de dificultad respiratoria aguda (SDRA)
El mercado del síndrome de dificultad respiratoria aguda (SDRA) también le proporciona un análisis detallado del mercado para el crecimiento de cada país en un mercado en particular. Además, proporciona información detallada sobre la estrategia de los actores del mercado y su presencia geográfica. Los datos están disponibles para el período histórico de 2011 a 2020.
Análisis del panorama competitivo y de la cuota de mercado del síndrome de dificultad respiratoria aguda (SDRA)
El panorama competitivo del mercado del síndrome de dificultad respiratoria aguda (SDRA) proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y la extensión de los productos, el dominio de las aplicaciones, la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado del síndrome de dificultad respiratoria aguda (SDRA).
Algunas de las principales empresas que se dedican al síndrome de dificultad respiratoria aguda (SDRA) son Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical (parte de ICU Medical, Inc.), ResMed, Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., EUROSETS y otros actores nacionales. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Numerosos contratos y acuerdos son iniciados también por empresas de todo el mundo, lo que también está acelerando el mercado del síndrome de dificultad respiratoria aguda (SDRA).
Por ejemplo,
- En mayo de 2021, Medtronic anunció el lanzamiento del sistema de monitoreo de las vías respiratorias SonarMed. El sistema utiliza tecnología acústica para detectar obstrucciones del tubo endotraqueal. Esto ha ayudado a la empresa a aumentar su cartera de productos.
- En julio de 2020, F. Hoffman-La Roche Ltd anunció el lanzamiento de una prueba rápida de anticuerpos contra el SARS-CoV-2. La prueba se lanzó en asociación con SD Biosenseor, Inc. Esto ha ayudado a la empresa a aumentar su cartera de productos.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias del actor del mercado están mejorando la huella de la empresa en el mercado del síndrome de dificultad respiratoria aguda, lo que también brinda beneficios para el crecimiento de las ganancias de la organización.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CAUSE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS
5.1 REGULATION IN U.S.:
5.2 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA
5.3 REGULATION FOR THE USE OF VENTILATOR AND ANESTHESIA GAS MACHINE BREATHING CIRCUIT DEVICES
5.4 LABELING OF MODIFIED DEVICES
5.5 REGULATION IN EUROPE:
5.6 REGULATION IN INDIA:
5.7 REGULATION IN JAPAN:
6 REGIONAL SUMMARY
6.1 NORTH AMERICA REGION
6.2 EUROPE REGION
6.3 ASIA-PACIFIC
6.4 SOUTH AMERICA
6.5 MIDDLE EAST AND AFRICA
7 PIPELINE ANALYSIS
8 INSURANCE REIMBURSEMENT
8.1 CENTER FOR MEDICARE SERVICES (CMS)–ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION)
8.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION
8.3 ABBOTT CODING GUIDE FOR ECMO
8.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS)
8.5 CERN HEALTH INSURANCE SCHEME
8.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – (MEDICARE & MEDICAID)
8.7 AMERICAN HOSPITAL ASSOCIATION
8.8 CONCLUSION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY
9.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS
9.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS
9.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES
9.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS
9.2 RESTRAINTS
9.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS
9.2.2 HIGH COST OF DEVICE AND TREATMENTS
9.2.3 LACK OF SKILLED WORKFORCE
9.3 OPPORTUNITIES
9.3.1 GROWING GERIATRIC POPULATION
9.3.2 RISING HEALTHCARE EXPENDITURE
9.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME
9.4 CHALLENGES
9.4.1 STRINGENT RULES & REGULATIONS
9.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES
10 IMPACT OF COVID-19 PANDEMIC ON THE ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE
11.1 OVERVIEW
11.2 DIAGNOSIS
11.2.1 IMAGING TESTS
11.2.1.1 CHEST X-RAY
11.2.1.2 CT SCAN
11.2.1.3 ULTRASOUND
11.2.1.4 OTHERS
11.2.2 BLOOD TEST
11.2.3 RESPIRATORY RATE
11.2.4 SPO2 TEST
11.2.5 OTHERS
11.3 TREATMENT
11.3.1 MECHANICAL VENTILATION
11.3.1.1 HIGH-FLOW NASAL O2
11.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE
11.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE
11.3.1.4 PRONE POSITIVE VENTILATION
11.3.1.5 OTHERS
11.3.2 CORTICOSTEROIDS
11.3.2.1 METHYLPREDNISOLONE
11.3.2.2 DEXAMETHASONE
11.3.2.3 OTHERS
11.3.3 ANTIVIRAL MEDICATION
11.3.3.1 REMDESIVIR
11.3.3.2 COMBINATION DRUGS
11.3.3.3 OTHERS
11.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
11.3.5 TOCILIZUMAB
11.3.6 OTHERS
12 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 PARENTERAL
12.2.1 INTRAVENOUS
12.2.2 INTRAMUSCULAR
12.3 ORAL
12.4 OTHERS
13 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE
13.1 OVERVIEW
13.2 CORONAVIRUS DISEASE 2019 (COVID-19)
13.3 SEPSIS
13.4 INHALATION OF HARMFUL SUBSTANCES
13.5 SEVERE PNEUMONIA
13.6 OTHERS
14 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACY
15.4 RETAIL PHARMACY
15.5 ONLINE PHARMACY
16 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION
16.1 ASIA-PACIFIC
16.1.1 JAPAN
16.1.2 CHINA
16.1.3 SOUTH KOREA
16.1.4 INDIA
16.1.5 AUSTRALIA
16.1.6 SINGAPORE
16.1.7 THAILAND
16.1.8 MALAYSIA
16.1.9 INDONESIA
16.1.10 PHILIPPINES
16.1.11 VIETNAM
16.1.12 REST OF ASIA-PACIFIC
17 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 GILEAD SCIENCES INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUS ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 TERUMO CORPORATION
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUS ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 GETINGE AB
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUS ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 LIVANOVA PLC
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 MEDTRONIC
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ALUNG TECHNOLOGIES, INC
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 ARMSTRONG MEDICAL
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BESMED HEALTH BUSINESS CORP.
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 DRÄGERWERK AG & CO. KGAA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 EUROSETS
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 F. HOFFMANN-LA ROCHE LTD
19.11.1 COMPANY SNAPSHOT
19.11.2 RECENT ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 FISHER & PAYKEL HEALTHCARE LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 FRESENIUS SE & CO. KGAA
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUS ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 HAMILTON MEDICAL
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 NIPRO
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUS ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 PFIZER INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUS ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENT
19.18 RESMED
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 SMITHS MEDICAL
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUS ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tablas
TABLE 1 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: PIPELINE ANALYSIS
TABLE 2 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC CORONAVIRUS DISEASE 2019 (COVID-19) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 33 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 ASIA-PACIFIC DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 ASIA-PACIFIC TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 46 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 JAPAN DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 JAPAN IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 JAPAN TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 54 JAPAN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 55 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 56 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 57 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 58 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 CHINA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 CHINA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 CHINA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 66 CHINA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 67 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 70 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 SOUTH KOREA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 SOUTH KOREA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 SOUTH KOREA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 78 SOUTH KOREA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 79 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 82 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 INDIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 INDIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 INDIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 INDIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 91 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 92 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 93 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 94 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 AUSTRALIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 AUSTRALIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 AUSTRALIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 102 AUSTRALIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 103 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 104 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 105 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 106 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 SINGAPORE DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 SINGAPORE IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 SINGAPORE TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 114 SINGAPORE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 115 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 118 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 THAILAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 THAILAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 THAILAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 126 THAILAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 127 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 128 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 129 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 130 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 MALAYSIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 MALAYSIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 MALAYSIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 135 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 138 MALAYSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 139 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 142 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 INDONESIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 INDONESIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 INDONESIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 149 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 150 INDONESIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 151 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 152 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 153 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 154 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 155 PHILIPPINES DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 PHILIPPINES IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 PHILIPPINES TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 162 PHILIPPINES PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 163 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 164 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 166 VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 VIETNAM DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 168 VIETNAM IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 VIETNAM TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 170 VIETNAM ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 VIETNAM CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 VIETNAM MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 174 VIETNAM PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 175 VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 176 VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 177 REST OF ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
Lista de figuras
FIGURE 1 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION
FIGURE 11 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS IS EXPECTED TO DRIVE THE ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
FIGURE 15 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2021
FIGURE 16 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 17 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 20 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2021
FIGURE 24 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2020-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2021
FIGURE 28 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DISTRIBUTION CHANNEL, 2021
FIGURE 32 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SNAPSHOT (2021)
FIGURE 36 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2021)
FIGURE 37 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 38 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 39 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE (2022-2029)
FIGURE 40 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2021 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
